Current status of antifungal resistance and its impact on clinical practice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Summary: Mortality linked to invasive fungal diseases remains very high despite the availability of novel antifungals and new therapeutic strategies. C andida albicans and A spergillus fumigatus account for most invasive mycosis produced by yeast or moulds, respectively. Other C andida non‐albicans are increasingly being reported and newly emerging, as well as cryptic, filamentous fungi often cause disseminated infections in immunocompromised hosts. Management of invasive fungal infections is becoming a challenge as emerging fungal pathogens generally show poor response to many antifungals. The ability of reference antifungal susceptibility testing methods to detect emerging resistance patterns, together with the molecular characterization of antifungal resistance mechanisms, are providing useful information to optimize the effectiveness of antifungal therapy. The current status of antifungal resistance epidemiology with special emphasis on the molecular resistant mechanisms that have been described in the main pathogenic fungal species are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 8×
“& Denning, D.W. (1998) In vitro activity of the echinocandin anti-”
BackgroundInfluentialAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“However, several recent reports of acquired resistance in clinical isolates of C. glabrata focus concern on this species because of a broad emergence of co-resistance over time to both azoles and echinocandins (Pfaller et al, 2012; Alexander et al, 2013).”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Cited by
Matsubara, V. H., Wang, Y., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7527-3 · Cited by 206
“, as the biofilm cells exhibit greater resistance to antifungals and host defenses compared to their planktonic or suspended counterparts (Alcazar-Fuoli and Mellado 2014).”
BackgroundFungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“This has the potential to contribute to clinical resistance [55] and it is extremely important to differentiate these low-level drug tolerance and adaptive mechanisms from the Fks1-mediated mechanisms that have been observed in clinical isolates and can result in treatment failure [55,129].”
BackgroundInfluentialThe Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans
Li, X., Cai, Q., Mei, H., Zhou, X., Shen, Y., Li, D., & Liu, W. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv070 · Cited by 64
Gupta, P. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10467.5395 · Cited by 43
Cross-feeding affects the target of resistance evolution to an antifungal drug
Durand, R., Jalbert-Ross, J., Fijarczyk, A., Dubé, A. K., & Landry, C. R. (2023) · PLOS Genetics · doi:10.1371/journal.pgen.1011002 · Cited by 14
Zhang, X., Bai, J., Wu, C.-L., Wu, Y., Zhao, Y., Song, W.-M., & Luo, X.-P. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2015.10.009 · Cited by 11
Metadata
- Authors
- Alcazar‐Fuoli, L., & Mellado, E.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-04-18
- Volume
- 166
- Issue
- 4
- Pages
- 471-484
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1964646367
- Cited by
- 117
- References
- 53
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.